Related Experiment Video

Updated: Jun 22, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer

Pankaj P Dangle1, Boriana Zaharieva, Hongtao Jia

  • 1Department of Urology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA.

Recent Patents on Anti-Cancer Drug Discovery
|June 13, 2009
PubMed

Insights

The Ras-MAPK pathway is crucial for cellular responses and often dysregulated in bladder cancer. Recent drug development focuses on targeted inhibitors with improved efficacy and reduced toxicity for advanced bladder cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Ras-MAPK pathway regulates cellular responses to stimuli.
  • Dysregulation of this pathway is common in various cancers, notably bladder cancer.
  • Components of the Ras-MAPK pathway are key targets for novel cancer drug development.

Purpose of the Study:

  • To review the significance of the Ras-MAPK pathway in cancer, particularly bladder cancer.
  • To discuss current therapeutic agents targeting this pathway.
  • To examine recent patents (2004-2008) related to Ras-MAPK pathway inhibitors for bladder cancer.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of drug development trends and patent filings.
  • Focus on tyrosine kinase inhibitors (FGFR, EGFR, ERBB2, PDGF) and other inhibitors (farnesyltransferase).

Main Results:

  • Multiple Ras-MAPK pathway inhibitors are in Phase II clinical trials for advanced bladder cancer.
  • Current drugs include small molecule tyrosine kinase, dual kinase, and farnesyltransferase inhibitors.
  • Recent patents indicate a trend towards more selective inhibitors with potential for better outcomes.

Conclusions:

  • The Ras-MAPK pathway is a vital target in bladder cancer therapy.
  • Targeted inhibitors show promise for improved therapeutic response and reduced toxicity.
  • Ongoing research and patent activity highlight the dynamic nature of drug development in this area.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...